Aventis Pharmaceuticals Inc.

Sanofi

Timothy A Gillespy

Hazel Joan Hunt

Michael L Edwards

Charles J Gardner

Andrew David Morley

Herve Bouchard

Tahir Nadeem Majid

Paul Joseph Cox

Shelley Amendola

Brian L Pedgrift

Christopher D Edlin

Stephanie Deprets

John G Jurcak

Frank Halley

Didier Babin

Dominique Damour

John Charles Reader

Conception Nemecek

Francois Clerc

Matthieu Barrague

Michael Cherry

Ramalinga M Dharanipragada

Kwon Yon Musick

Dorothea Kominos

Chantal Carrez

Justine Yeun Quai Lai

Laurence Gauzy

Nawaz Mohammed Khan

Olivier Houille

Daniel N A Bezard

Yan Du

Alain Le-Brun

Lloyd J Payne

Hazel Joan Dyke

Philip M Weintraub

Elizabeth Allen

Elsa Amandine Dechaux

Ashfaq Ahmad Parkar

Sungtaek Lim

Keith John Harris

Bin Cao

Ashfaq Ahmed Parkar

David Stefany

Phillip Marvin Weintraub

Stephanie D Deprets

Paul Eynott

Ray Boffey

Kin T Yu

Joacy C Aguiar

Asher Zilberstein

Elizabeth M Allen

Ray Argenta Discovery Ltd Boffey

The invention is directed to a compound of formula (I): and the prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs. Such a compound has valuable pharmaceutical properties, in particular the ability to inhibit protein kinases.

Kinase inhibitor

The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Benzimidazoles

The present invention is directed to a compound of Formula (I) wherein Cy, Cy, L, L, and Rare as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).

2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists

The invention is directed to physiologically active compounds of general formula (I):&#x2014; and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Azaindoles for inhibiting aurora2 and other kinases

Thienopyrazoles of formula I, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical uses in the treatment of disease states capable of being modulated by the inhibition of the protein kinases, in particular interleukin-2 inducible tyrosine kinase (ITK). 

Thienopyrazoles

The invention is directed to physiologically active compounds of general formula (I):and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Azaindoles

The invention is directed to physiologically active compounds of the general formula (Ix)and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Growing community of inventors

Hillsborough, NJ, United States of America

Timothy A Gillespy